{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:10:52Z","timestamp":1794633052336,"version":"4.9.1"},"reference-count":240,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>After decades of disappointment, three disease-modifying therapies for Alzheimer\u2019s disease (AD) have been approved since 2021. Burgeoning clinical data on these amyloid \u03b2-protein (A\u03b2) targeting drugs validate the amyloid cascade hypothesis as a molecular roadmap for the development of yet more effective therapeutics and offer a template for drugging other AD-associated aggregation-prone proteins. While there remains much to be learned about the molecular pathology of AD, the current state of knowledge is sufficient to expedite the delivery of new drugs. Mindful of the urgent need of patients, we recommend prioritizing efforts in four directions: finishing the job on A\u03b2, accelerating and diversifying efforts on tau, and expanding discovery on apolipoprotein E and \u237a-synuclein. For each target, we explain the scientific premise, current efforts, and possible new approaches. In the short- and medium-term, we advocate focusing on the technical innovations required to better drug these already well validated targets. While the focus of this review is on expediating development of monotherapies, the subsequent approval of such agents will enable add-on or combination approaches best suited to individual patients.\n<\/jats:p>","DOI":"10.1186\/s13024-025-00872-7","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:01:03Z","timestamp":1754456463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A manifesto for Alzheimer\u2019s disease drug discovery in the era of disease-modifying therapies"],"prefix":"10.1186","volume":"20","author":[{"given":"Heike","family":"Hering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Glajch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weihofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-7308","authenticated-orcid":false,"given":"Dominic M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"872_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/s0006-291x(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885\u201390. https:\/\/doi.org\/10.1016\/s0006-291x(84)80190-4.","journal-title":"Biochem Biophys Res Commun"},{"key":"872_CR2","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer A. Uber eigenartige Erkrankung der Hirnrinde. All Z Psychiatr. 1907;64:146\u20138.","journal-title":"All Z Psychiatr"},{"key":"872_CR3","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci. 1986;83:4913\u20137. https:\/\/doi.org\/10.1073\/pnas.83.13.4913.","journal-title":"Proc Natl Acad Sci"},{"key":"872_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"872_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-v","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12:383\u20138. https:\/\/doi.org\/10.1016\/0165-6147(91)90609-v.","journal-title":"Trends Pharmacol Sci"},{"key":"872_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u201398. https:\/\/doi.org\/10.1016\/0896-6273(91)90052-2.","journal-title":"Neuron"},{"key":"872_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306\u201318. https:\/\/doi.org\/10.1038\/s41573-022-00391-w.","journal-title":"Nat Rev Drug Discov"},{"key":"872_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHV Dyck","year":"2023","unstructured":"Dyck CHV, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl Journal of Medicine. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl Journal of Medicine"},{"key":"872_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/hypertensionaha.111.178962","volume":"59","author":"NS Shah","year":"2012","unstructured":"Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma \u03b2-amyloid, and the risk for Alzheimer disease: the Honolulu Asia aging study. Hypertension. 2012;59:780\u20136. https:\/\/doi.org\/10.1161\/hypertensionaha.111.178962.","journal-title":"Hypertension"},{"key":"872_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54:412\u201336. https:\/\/doi.org\/10.1038\/s41588-022-01024-z.","journal-title":"Nat Genet"},{"key":"872_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/archneur.60.2.194","volume":"60","author":"MC Morris","year":"2003","unstructured":"Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol. 2003;60:194\u2013200. https:\/\/doi.org\/10.1001\/archneur.60.2.194.","journal-title":"Arch Neurol"},{"key":"872_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"872_CR14","unstructured":"U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation. Early Alzheimer\u2019s disease: developing drugs for treatment, guidelines for industry. 2018."},{"key":"872_CR15","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.6474172","volume":"225","author":"BT Hyman","year":"1984","unstructured":"Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer\u2019s disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168\u201370. https:\/\/doi.org\/10.1126\/science.6474172.","journal-title":"Science"},{"key":"872_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/bf00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359. https:\/\/doi.org\/10.1007\/bf00308809.","journal-title":"Acta Neuropathol"},{"key":"872_CR17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/wnl.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800. https:\/\/doi.org\/10.1212\/wnl.58.12.1791.","journal-title":"Neurology"},{"key":"872_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27:871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"key":"872_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"872_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/nm1438","volume":"12","author":"RJ Bateman","year":"2006","unstructured":"Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856\u201361. https:\/\/doi.org\/10.1038\/nm1438.","journal-title":"Nat Med"},{"key":"872_CR21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/brain\/awz066","volume":"142","author":"G Brinkmalm","year":"2019","unstructured":"Brinkmalm G, Hong W, Wang Z, et al. Identification of neurotoxic cross-linked amyloid-\u03b2 dimers in the Alzheimer\u2019s brain. Brain. 2019;142:1441\u201357. https:\/\/doi.org\/10.1093\/brain\/awz066.","journal-title":"Brain"},{"key":"872_CR22","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/s41380-022-01518-6","volume":"27","author":"D Petit","year":"2022","unstructured":"Petit D, Fern\u00e1ndez SG, Zoltowska KM, et al. A\u03b2 profiles generated by Alzheimer\u2019s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry. 2022;27:2821\u201332. https:\/\/doi.org\/10.1038\/s41380-022-01518-6.","journal-title":"Mol Psychiatry"},{"key":"872_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/s1474-4422(24)00236-9","volume":"23","author":"SA Schultz","year":"2024","unstructured":"Schultz SA, Liu L, Schultz AP, et al. \u03b3-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer\u2019s disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2024;23:913\u201324. https:\/\/doi.org\/10.1016\/s1474-4422(24)00236-9.","journal-title":"Lancet Neurol"},{"key":"872_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1042\/bst0350416","volume":"35","author":"DM Walsh","year":"2007","unstructured":"Walsh DM, Minogue AM, Sala Frigerio C, et al. The APP family of proteins: similarities and differences. Biochem Soc Trans. 2007;35:416\u201320. https:\/\/doi.org\/10.1042\/bst0350416.","journal-title":"Biochem Soc Trans"},{"key":"872_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/cn900015v","volume":"1","author":"E Hellstrand","year":"2010","unstructured":"Hellstrand E, Boland B, Walsh DM, Linse S. Amyloid \u03b2-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci. 2010;1:13\u20138. https:\/\/doi.org\/10.1021\/cn900015v.","journal-title":"ACS Chem Neurosci"},{"key":"872_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.sbi.2021.05.004","volume":"70","author":"S Linse","year":"2021","unstructured":"Linse S. Toward the equilibrium and kinetics of amyloid peptide self-assembly. Curr Opin Struct Biol. 2021;70:87\u201398. https:\/\/doi.org\/10.1016\/j.sbi.2021.05.004.","journal-title":"Curr Opin Struct Biol"},{"key":"872_CR27","unstructured":"Yan Jin IG, Yun-Ju Cheng, Ilke Tunali, Sergey Shcherbinin, David Perahia, Krista Phipps, Kevin Biglan, Mark Mintun, Matan Dabora, Miroslaw Brys, editor Safety and Amyloid Plaque Reduction Effects of Remternetug in Patients with Alzheimer\u2019s Disease: Interim Analysis from a Phase 1 Study. Gothernburg: 2023 AD\/PD Conference; 2023."},{"key":"872_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76:908\u201320. https:\/\/doi.org\/10.1016\/j.neuron.2012.10.029.","journal-title":"Neuron"},{"key":"872_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"key":"872_CR30","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"key":"872_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"872_CR32","unstructured":"Luka Kulic FA, Gregory Klein, Carsten Hofmann, Stella Yilmaz, Jo\u00e3o A. Abrantes, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, editor Latest interim results from the Brainshuttle AD study, a phase 1b\/2a study of trontinemab in people with Alzheimer\u2019s disease. J Prev Alzheimer's Dis. 2025;12(Suppl 1):Abstract LB02."},{"key":"872_CR33","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N Engl J Med. 2023;389:1862\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2304430.","journal-title":"N Engl J Med"},{"key":"872_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49\u201360. https:\/\/doi.org\/10.1016\/j.neuron.2013.10.061.","journal-title":"Neuron"},{"key":"872_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","volume":"22","author":"F Weber","year":"2018","unstructured":"Weber F, Bohrmann B, Niewoehner J, et al. Brain shuttle antibody for Alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Rep. 2018;22:149\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.019.","journal-title":"Cell Rep"},{"key":"872_CR36","doi-asserted-by":"publisher","unstructured":"Pizzo ME, Plowey ED, Khoury N, et al. Engineering anti-amyloid antibodies with transferrin receptor targeting improves safety and brain biodistribution. bioRxiv 2024:2024.2007.2026.604664. https:\/\/doi.org\/10.1101\/2024.07.26.604664.","DOI":"10.1101\/2024.07.26.604664"},{"key":"872_CR37","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bbi.2010.05.010","volume":"24","author":"YJ Wang","year":"2010","unstructured":"Wang YJ, Gao CY, Yang M, et al. Intramuscular delivery of a single chain antibody gene prevents brain A\u03b2 deposition and cognitive impairment in a mouse model of Alzheimer\u2019s disease. Brain Behav Immun. 2010;24:1281\u201393. https:\/\/doi.org\/10.1016\/j.bbi.2010.05.010.","journal-title":"Brain Behav Immun"},{"key":"872_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057606","volume":"8","author":"M Shimada","year":"2013","unstructured":"Shimada M, Abe S, Takahashi T, et al. Prophylaxis and treatment of Alzheimer\u2019s disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One. 2013;8: e57606. https:\/\/doi.org\/10.1371\/journal.pone.0057606.","journal-title":"PLoS One"},{"key":"872_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s1474-4422(02)00023-6","volume":"1","author":"K Senior","year":"2002","unstructured":"Senior K. Dosing in phase II trial of Alzheimer\u2019s vaccine suspended. Lancet Neurol. 2002;1:3. https:\/\/doi.org\/10.1016\/s1474-4422(02)00023-6.","journal-title":"Lancet Neurol"},{"key":"872_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"D Schenk","year":"2002","unstructured":"Schenk D. Amyloid-beta immunotherapy for Alzheimer\u2019s disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824\u20138. https:\/\/doi.org\/10.1038\/nrn938.","journal-title":"Nat Rev Neurosci"},{"key":"872_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.Wnl.0000159740.16984.3c","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553\u201362. https:\/\/doi.org\/10.1212\/01.Wnl.0000159740.16984.3c.","journal-title":"Neurology"},{"key":"872_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease. Neuron. 2003;38:547\u201354. https:\/\/doi.org\/10.1016\/s0896-6273(03)00294-0.","journal-title":"Neuron"},{"key":"872_CR43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448\u201352. https:\/\/doi.org\/10.1038\/nm840.","journal-title":"Nat Med"},{"key":"872_CR44","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll JAR, Buckland GR, Harrison CH, et al. Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease. Brain. 2019;142:2113\u201326. https:\/\/doi.org\/10.1093\/brain\/awz142.","journal-title":"Brain"},{"key":"872_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","volume":"17","author":"E McDade","year":"2021","unstructured":"McDade E, Voytyuk I, Aisen P, et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol. 2021;17:703\u201314. https:\/\/doi.org\/10.1038\/s41582-021-00545-1.","journal-title":"Nat Rev Neurol"},{"key":"872_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","volume":"78","author":"R Sperling","year":"2021","unstructured":"Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b\/3 clinical trial. JAMA Neurol. 2021;78:293\u2013301. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4857.","journal-title":"JAMA Neurol"},{"key":"872_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1279740","volume":"16","author":"G Nordvall","year":"2023","unstructured":"Nordvall G, Lundkvist J, Sandin J. Gamma-secretase modulators: a promising route for the treatment of Alzheimer\u2019s disease. Front Mol Neurosci. 2023;16: 1279740. https:\/\/doi.org\/10.3389\/fnmol.2023.1279740.","journal-title":"Front Mol Neurosci"},{"key":"872_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz M, Silvestre S. Alzheimer\u2019s disease: recent treatment strategies. Eur J Pharmacol. 2020;887: 173554. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173554.","journal-title":"Eur J Pharmacol"},{"key":"872_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"AM Wessels","year":"2020","unstructured":"Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 2020;77:199\u2013209. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3988.","journal-title":"JAMA Neurol"},{"key":"872_CR50","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMc1813435","volume":"380","author":"D Henley","year":"2019","unstructured":"Henley D, Raghavan N, Sperling R, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease. N Engl J Med. 2019;380:1483\u20135. https:\/\/doi.org\/10.1056\/NEJMc1813435.","journal-title":"N Engl J Med"},{"key":"872_CR51","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med. 2019;380:1408\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1812840.","journal-title":"N Engl J Med"},{"key":"872_CR52","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3233\/jad-160701","volume":"55","author":"G Cebers","year":"2017","unstructured":"Cebers G, Alexander RC, Haeberlein SB, et al. AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease. 2017;55:1039\u201353. https:\/\/doi.org\/10.3233\/jad-160701.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"872_CR53","doi-asserted-by":"publisher","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci Transl Med. 2016;8:363ra150. https:\/\/doi.org\/10.1126\/scitranslmed.aad9704.","journal-title":"Sci Transl Med"},{"key":"872_CR54","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2018;378:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1706441.","journal-title":"N Engl J Med"},{"key":"872_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369:341\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1210951.","journal-title":"N Engl J Med"},{"key":"872_CR56","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72:1324\u201333. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0607.","journal-title":"JAMA Neurol"},{"key":"872_CR57","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1016\/j.molcel.2023.10.029","volume":"83","author":"P Hou","year":"2023","unstructured":"Hou P, Zielonka M, Serneels L, et al. The \u03b3-secretase substrate proteome and its role in cell signaling regulation. Mol Cell. 2023;83:4106-4122.e4110. https:\/\/doi.org\/10.1016\/j.molcel.2023.10.029.","journal-title":"Mol Cell"},{"key":"872_CR58","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/19083","volume":"398","author":"B De Strooper","year":"1999","unstructured":"De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518\u201322. https:\/\/doi.org\/10.1038\/19083.","journal-title":"Nature"},{"key":"872_CR59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.aaw0930","volume":"363","author":"R Zhou","year":"2019","unstructured":"Zhou R, Yang G, Guo X, et al. Recognition of the amyloid precursor protein by human \u03b3-secretase. Science. 2019;363:363. https:\/\/doi.org\/10.1126\/science.aaw0930.","journal-title":"Science"},{"key":"872_CR60","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s44318-024-00057-w","volume":"43","author":"B De Strooper","year":"2024","unstructured":"De Strooper B, Karran E. New precision medicine avenues to the prevention of Alzheimer\u2019s disease from insights into the structure and function of \u03b3-secretases. EMBO J. 2024;43:887\u2013903. https:\/\/doi.org\/10.1038\/s44318-024-00057-w.","journal-title":"EMBO J"},{"key":"872_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00401-024-02756-4","volume":"148","author":"A Kasri","year":"2024","unstructured":"Kasri A, Camporesi E, Gkanatsiou E, et al. Amyloid-\u03b2 peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer\u2019s disease with APPdup and Down syndrome. Acta Neuropathol. 2024;148:8. https:\/\/doi.org\/10.1007\/s00401-024-02756-4.","journal-title":"Acta Neuropathol"},{"key":"872_CR62","unstructured":"Lott APD, Alam M, Cantrill C, Croney R, Alcaraz F, Rodr\u00edguez Sarmiento RM, Lindemann L, Mueller L, Mueggler T, Vardar T, Tortelli R, Sturm S, Gerlach I, editor RG6289, a new \u03b3-secretase modulator for the treatment of Alzheimer\u2019s disease: Dose selection for a Phase II trial based on population PK\/PD modeling. J Prev Alzheimer's Dis. 2023;10(Suppl 1):Abstract PO17."},{"key":"872_CR63","doi-asserted-by":"publisher","first-page":"(TBD)","DOI":"10.1002\/alz.084521","volume":"20","author":"S Cohen","year":"2024","unstructured":"Cohen S, Ducharme S, Brosch JR, et al. Single ascending dose results from an ongoing phase 1 study of mivelsiran (ALN-APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia. 2024;20:(TBD).","journal-title":"Alzheimer's and Dementia"},{"key":"872_CR64","doi-asserted-by":"publisher","first-page":"e12498","DOI":"10.1002\/trc2.12498","volume":"10","author":"S Abushakra","year":"2024","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, et al. APOLLOE4 phase 3 study of oral ALZ-801\/valiltramiprosate in APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: trial design and baseline characteristics. Alzheimers Dement (N Y). 2024;10:e12498. https:\/\/doi.org\/10.1002\/trc2.12498.","journal-title":"Alzheimers Dement (N Y)"},{"key":"872_CR65","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.2147\/ijn.S444115","volume":"18","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Liu Y, Ruan S, Hu Y. Current anti-amyloid-\u03b2 therapy for Alzheimer\u2019s disease treatment: from clinical research to nanomedicine. Int J Nanomedicine. 2023;18:7825\u201345. https:\/\/doi.org\/10.2147\/ijn.S444115.","journal-title":"Int J Nanomedicine"},{"key":"872_CR66","doi-asserted-by":"publisher","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","volume":"286","author":"S Jawhar","year":"2011","unstructured":"Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-\u03b2 (A\u03b2): a hatchet man in Alzheimer disease. J Biol Chem. 2011;286:38825\u201332. https:\/\/doi.org\/10.1074\/jbc.R111.288308.","journal-title":"J Biol Chem"},{"key":"872_CR67","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","volume":"27","author":"TA Bayer","year":"2022","unstructured":"Bayer TA. Pyroglutamate A\u03b2 cascade as drug target in Alzheimer\u2019s disease. Mol Psychiatry. 2022;27:1880\u20135. https:\/\/doi.org\/10.1038\/s41380-021-01409-2.","journal-title":"Mol Psychiatry"},{"key":"872_CR68","doi-asserted-by":"publisher","unstructured":"Hartlage-R\u00fcbsamen M, Bluhm A, Piechotta A, et al. Immunohistochemical evidence from APP-transgenic mice for glutaminyl cyclase as drug target to diminish pE-abeta formation. Molecules 2018;23. https:\/\/doi.org\/10.3390\/molecules23040924.","DOI":"10.3390\/molecules23040924"},{"key":"872_CR69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/jpet.117.240614","volume":"362","author":"T Hoffmann","year":"2017","unstructured":"Hoffmann T, Meyer A, Heiser U, et al. Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer\u2019s disease\u2014studies on relation to effective target occupancy. J Pharmacol Exp Ther. 2017;362:119\u201330. https:\/\/doi.org\/10.1124\/jpet.117.240614.","journal-title":"J Pharmacol Exp Ther"},{"key":"872_CR70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13195-021-00882-9","volume":"13","author":"EGB Vijverberg","year":"2021","unstructured":"Vijverberg EGB, Axelsen TM, Bihlet AR, et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. Alzheimers Res Ther. 2021;13:142. https:\/\/doi.org\/10.1186\/s13195-021-00882-9.","journal-title":"Alzheimers Res Ther"},{"key":"872_CR71","unstructured":"Vivoryon Therapeutics N.V. Provides update on VIVIAD phase 2b study of varoglutamstat in early Alzheimer\u2019s disease [press release]. 2024. https:\/\/www.vivoryon.com\/vivoryon-therapeutics-n-v-provides-update-on-viviad-phase-2b-study-of-varoglutamstat-in-earlyalzheimers-disease\/."},{"key":"872_CR72","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.medj.2024.08.004","volume":"5","author":"Y Hu","year":"2024","unstructured":"Hu Y, Cho M, Sachdev P, et al. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer\u2019s disease. Med. 2024;5:1206\u201326. https:\/\/doi.org\/10.1016\/j.medj.2024.08.004.","journal-title":"Med"},{"key":"872_CR73","doi-asserted-by":"publisher","first-page":"e095213","DOI":"10.1002\/alz.095213","volume":"20","author":"T Mueggler","year":"2024","unstructured":"Mueggler T, Portron A, Poirier A, et al. Pharmacodynamic effect of a new \u03b3-secretase modulator, RG6289, on CSF amyloid-\u03b2 peptides in a randomized phase I study. Alzheimers Dement. 2024;20:e095213. https:\/\/doi.org\/10.1002\/alz.095213.","journal-title":"Alzheimers Dement"},{"key":"872_CR74","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ana.27175","volume":"97","author":"M Noguchi-Shinohara","year":"2025","unstructured":"Noguchi-Shinohara M, Shuta K, Murakami H, et al. Lecanemab-associated amyloid-\u03b2 protofibril in cerebrospinal fluid correlates with biomarkers of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 2025;97:993\u20131006. https:\/\/doi.org\/10.1002\/ana.27175.","journal-title":"Ann Neurol"},{"key":"872_CR75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ana.25513","volume":"86","author":"T Yang","year":"2019","unstructured":"Yang T, Dang Y, Ostaszewski B, et al. Target engagement in an Alzheimer trial: Crenezumab lowers amyloid \u03b2 oligomers in cerebrospinal fluid. Ann Neurol. 2019;86:215\u201324. https:\/\/doi.org\/10.1002\/ana.25513.","journal-title":"Ann Neurol"},{"key":"872_CR76","unstructured":"FDA clears first blood test used in diagnosing alzheimer\u2019s disease [press release]. 2025.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease."},{"key":"872_CR77","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1212\/WNL.0000000000211295","volume":"104","author":"HT Feaster","year":"2025","unstructured":"Feaster HT, Sundell K, Hyland M, et al. ALTITUDE-AD: use of a validated plasma pTau217 assay to screen potential participants in an ongoing randomized, double-blind, placebo-controlled phase 2 study of sabirnetug for early Alzheimer\u2019s disease (S15.008). Neurology. 2025;104:3870. https:\/\/doi.org\/10.1212\/WNL.0000000000211295.","journal-title":"Neurology"},{"key":"872_CR78","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"key":"872_CR79","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez JF, Lopera F, O\u2019Hare M, et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680\u20133. https:\/\/doi.org\/10.1038\/s41591-019-0611-3.","journal-title":"Nat Med"},{"key":"872_CR80","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-023-02318-3","volume":"29","author":"F Lopera","year":"2023","unstructured":"Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer\u2019s disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023;29:1243\u201352. https:\/\/doi.org\/10.1038\/s41591-023-02318-3.","journal-title":"Nat Med"},{"key":"872_CR81","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","volume":"99","author":"KH Strang","year":"2019","unstructured":"Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019;99:912\u201328. https:\/\/doi.org\/10.1038\/s41374-019-0197-x.","journal-title":"Lab Invest"},{"key":"872_CR82","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665\u2013704. https:\/\/doi.org\/10.1007\/s00401-017-1707-9.","journal-title":"Acta Neuropathol"},{"key":"872_CR83","doi-asserted-by":"publisher","first-page":"10851","DOI":"10.1523\/jneurosci.0387-15.2015","volume":"35","author":"D Kanmert","year":"2015","unstructured":"Kanmert D, Cantlon A, Muratore CR, et al. C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci. 2015;35:10851\u201365. https:\/\/doi.org\/10.1523\/jneurosci.0387-15.2015.","journal-title":"J Neurosci"},{"key":"872_CR84","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barth\u00e9lemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97:1284-1298.e1287. https:\/\/doi.org\/10.1016\/j.neuron.2018.02.015.","journal-title":"Neuron"},{"key":"872_CR85","doi-asserted-by":"publisher","first-page":"5870","DOI":"10.1523\/jneurosci.0082-23.2023","volume":"43","author":"T Ondrejcak","year":"2023","unstructured":"Ondrejcak T, Klyubin I, Hu NW, et al. Tau and amyloid \u03b2 protein in patient-derived aqueous brain extracts act concomitantly to disrupt long-term potentiation in vivo. J Neurosci. 2023;43:5870\u20139. https:\/\/doi.org\/10.1523\/jneurosci.0082-23.2023.","journal-title":"J Neurosci"},{"key":"872_CR86","doi-asserted-by":"publisher","first-page":"fcae333","DOI":"10.1093\/braincomms\/fcae333","volume":"6","author":"NW Hu","year":"2024","unstructured":"Hu NW, Ondrejcak T, Klyubin I, et al. Patient-derived tau and amyloid-\u03b2 facilitate long-term depression in vivo: role of tumour necrosis factor-\u03b1 and the integrated stress response. Brain Commun. 2024;6:fcae333. https:\/\/doi.org\/10.1093\/braincomms\/fcae333.","journal-title":"Brain Commun"},{"key":"872_CR87","doi-asserted-by":"publisher","first-page":"12887","DOI":"10.1523\/jneurosci.2107-13.2013","volume":"33","author":"SL DeVos","year":"2013","unstructured":"DeVos SL, Goncharoff DK, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33:12887\u201397. https:\/\/doi.org\/10.1523\/jneurosci.2107-13.2013.","journal-title":"J Neurosci"},{"key":"872_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm5527","volume":"14","author":"E Shao","year":"2022","unstructured":"Shao E, Chang CW, Li Z, et al. TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model. Sci Transl Med. 2022;14: eabm5527. https:\/\/doi.org\/10.1126\/scitranslmed.abm5527.","journal-title":"Sci Transl Med"},{"key":"872_CR89","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.abb8255","volume":"371","author":"CW Chang","year":"2021","unstructured":"Chang CW, Shao E, Mucke L. Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science. 2021;371:371. https:\/\/doi.org\/10.1126\/science.abb8255.","journal-title":"Science"},{"key":"872_CR90","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.neuron.2020.01.038","volume":"106","author":"C Tai","year":"2020","unstructured":"Tai C, Chang CW, Yu GQ, et al. Tau reduction prevents key features of autism in mouse models. Neuron. 2020;106:421-437.e411. https:\/\/doi.org\/10.1016\/j.neuron.2020.01.038.","journal-title":"Neuron"},{"key":"872_CR91","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrn3887","volume":"16","author":"J Brettschneider","year":"2015","unstructured":"Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16:109\u201320. https:\/\/doi.org\/10.1038\/nrn3887.","journal-title":"Nat Rev Neurosci"},{"key":"872_CR92","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrn.2016.13","volume":"17","author":"DM Walsh","year":"2016","unstructured":"Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016;17:251\u201360. https:\/\/doi.org\/10.1038\/nrn.2016.13.","journal-title":"Nat Rev Neurosci"},{"key":"872_CR93","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M, Kong J, O\u2019Gorman J, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nat Aging. 2023;3:1591\u2013601. https:\/\/doi.org\/10.1038\/s43587-023-00523-w.","journal-title":"Nat Aging"},{"key":"872_CR94","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/wnl.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, et al. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: lauriet. Neurology. 2023;101:e1391\u2013401. https:\/\/doi.org\/10.1212\/wnl.0000000000207663.","journal-title":"Neurology"},{"key":"872_CR95","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000208061","volume":"102","author":"AS Fleisher","year":"2024","unstructured":"Fleisher AS, Munsie LM, Perahia DGS, et al. Assessment of efficacy and safety of zagotenemab: results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease. Neurology. 2024;102: e208061. https:\/\/doi.org\/10.1212\/wnl.0000000000208061.","journal-title":"Neurology"},{"key":"872_CR96","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79:758\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1375.","journal-title":"JAMA Neurol"},{"key":"872_CR97","doi-asserted-by":"publisher","first-page":"e12471","DOI":"10.1002\/trc2.12471","volume":"10","author":"X Zhou","year":"2024","unstructured":"Zhou X, Zou H, Lutz MW, et al. Assessing tilavonemab efficacy in early Alzheimer\u2019s disease via longitudinal item response theory modeling. Alzheimers Dement (N Y). 2024;10:e12471. https:\/\/doi.org\/10.1002\/trc2.12471.","journal-title":"Alzheimers Dement (N Y)"},{"key":"872_CR98","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease. Alzheimers Dement. 2019;15:487\u201396. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.010.","journal-title":"Alzheimers Dement"},{"key":"872_CR99","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie K, Barth\u00e9lemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain. 2021;144:515\u201327. https:\/\/doi.org\/10.1093\/brain\/awaa373.","journal-title":"Brain"},{"key":"872_CR100","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29:1954\u201363. https:\/\/doi.org\/10.1038\/s41591-023-02443-z.","journal-title":"Nat Med"},{"key":"872_CR101","unstructured":"Barton ME. editor Results from TOGETHER, a Phase II study of bepranemab in prodromal\u2013mild AD. J Prev Alzheimer's Dis. 2025;12(Suppl 1):Abstract LBS3."},{"key":"872_CR102","doi-asserted-by":"publisher","first-page":"e082771","DOI":"10.1002\/alz.082771","volume":"19","author":"J Zhou","year":"2023","unstructured":"Zhou J, Rawal S, Yagi T, et al. E2814: an anti-tau therapy engages its CNS target and affects the downstream tangle-specific biomarker MTBR-tau243 in dominantly inherited Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:e082771. https:\/\/doi.org\/10.1002\/alz.082771.","journal-title":"Alzheimers Dement"},{"key":"872_CR103","unstructured":"Wildsmith K. editor Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD. J Prev Alzheimer's Dis. 2025;12(Suppl 1):Abstract OC04."},{"key":"872_CR104","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1038\/s41598-018-21596-3","volume":"8","author":"F Biundo","year":"2018","unstructured":"Biundo F, Del Prete D, Zhang H, Arancio O, D\u2019Adamio L. A role for tau in learning, memory and synaptic plasticity. Sci Rep. 2018;8:3184. https:\/\/doi.org\/10.1038\/s41598-018-21596-3.","journal-title":"Sci Rep"},{"key":"872_CR105","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1242\/jcs.222059","volume":"132","author":"S Yi","year":"2019","unstructured":"Yi S, Liu Q, Wang X, et al. Tau modulates Schwann cell proliferation, migration and differentiation following peripheral nerve injury. J Cell Sci. 2019;132:132. https:\/\/doi.org\/10.1242\/jcs.222059.","journal-title":"J Cell Sci"},{"key":"872_CR106","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0304-3940(99)00964-7","volume":"279","author":"S Ikegami","year":"2000","unstructured":"Ikegami S, Harada A, Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett. 2000;279:129\u201332. https:\/\/doi.org\/10.1016\/s0304-3940(99)00964-7.","journal-title":"Neurosci Lett"},{"key":"872_CR107","doi-asserted-by":"publisher","first-page":"eabe1611","DOI":"10.1126\/sciadv.abe1611","volume":"7","author":"S Wegmann","year":"2021","unstructured":"Wegmann S, DeVos SL, Zeitler B, et al. Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. Science Advances. 2021;7:eabe1611. https:\/\/doi.org\/10.1126\/sciadv.abe1611.","journal-title":"Science Advances"},{"key":"872_CR108","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards AL, Collins JA, Junge C, et al. Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2023;80:1344\u201352. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3861.","journal-title":"JAMA Neurol"},{"key":"872_CR109","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, et al. Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29:1437\u201347. https:\/\/doi.org\/10.1038\/s41591-023-02326-3.","journal-title":"Nat Med"},{"key":"872_CR110","unstructured":"Ziogas N, Wu S, Li Y, et al. Exploratory clinical outcomes from the BIIB080 Phase 1b multiple ascending dose and long term extension study in mild Alzheimer\u2019s disease. J Prev Alzheimer's Dis. 2023;10(Suppl 1):Abstract LB09."},{"key":"872_CR111","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker SJ, Thayer MB, Kim C, et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci Transl Med. 2024;16: eadi2245. https:\/\/doi.org\/10.1126\/scitranslmed.adi2245.","journal-title":"Sci Transl Med"},{"key":"872_CR112","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1021\/acs.bioconjchem.3c00393","volume":"34","author":"T Sela","year":"2023","unstructured":"Sela T, Mans\u00f8 M, Siegel M, et al. Diligent design enables antibody-ASO conjugates with optimal pharmacokinetic properties. Bioconjug Chem. 2023;34:2096\u2013111. https:\/\/doi.org\/10.1021\/acs.bioconjchem.3c00393.","journal-title":"Bioconjug Chem"},{"key":"872_CR113","doi-asserted-by":"publisher","first-page":"114861","DOI":"10.1016\/j.addr.2023.114861","volume":"197","author":"P Khare","year":"2023","unstructured":"Khare P, Edgecomb SX, Hamadani CM, Tanner EE, Manickam DS. Lipid nanoparticle-mediated drug delivery to the brain. Adv Drug Deliv Rev. 2023;197:114861. https:\/\/doi.org\/10.1016\/j.addr.2023.114861.","journal-title":"Adv Drug Deliv Rev"},{"key":"872_CR114","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673\u201394. https:\/\/doi.org\/10.1038\/s41573-020-0075-7.","journal-title":"Nat Rev Drug Discov"},{"key":"872_CR115","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","volume":"62","author":"JM Sasso","year":"2023","unstructured":"Sasso JM, Tenchov R, Wang D, et al. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry. 2023;62:601\u201323. https:\/\/doi.org\/10.1021\/acs.biochem.2c00245.","journal-title":"Biochemistry"},{"key":"872_CR116","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/17460441.2024.2306845","volume":"19","author":"T Lemaitre","year":"2024","unstructured":"Lemaitre T, Cornu M, Schwalen F, et al. Molecular glue degraders: exciting opportunities for novel drug discovery. Expert Opin Drug Discov. 2024;19:433\u201349. https:\/\/doi.org\/10.1080\/17460441.2024.2306845.","journal-title":"Expert Opin Drug Discov"},{"key":"872_CR117","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/d41573-024-00170-9","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. Protein degraders push into novel target space. Nat Rev Drug Discov. 2024;23:799\u2013802. https:\/\/doi.org\/10.1038\/d41573-024-00170-9.","journal-title":"Nat Rev Drug Discov"},{"key":"872_CR118","doi-asserted-by":"publisher","unstructured":"Sincere NI, Anand K, Ashique S, Yang J, You C. PROTACs: Emerging targeted protein degradation approaches for advanced druggable strategies. Molecules 2023;28. https:\/\/doi.org\/10.3390\/molecules28104014.","DOI":"10.3390\/molecules28104014"},{"key":"872_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104178","volume":"29","author":"D Pliatsika","year":"2024","unstructured":"Pliatsika D, Blatter C, Riedl R. Targeted protein degradation: current molecular targets, localization, and strategies. Drug Discovery Today. 2024;29: 104178. https:\/\/doi.org\/10.1016\/j.drudis.2024.104178.","journal-title":"Drug Discovery Today"},{"key":"872_CR120","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.jmb.2014.01.004","volume":"426","author":"SA Yuzwa","year":"2014","unstructured":"Yuzwa SA, Cheung AH, Okon M, McIntosh LP, Vocadlo DJ. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J Mol Biol. 2014;426:1736\u201352. https:\/\/doi.org\/10.1016\/j.jmb.2014.01.004.","journal-title":"J Mol Biol"},{"key":"872_CR121","doi-asserted-by":"publisher","first-page":"34472","DOI":"10.1074\/jbc.R114.601351","volume":"289","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ. The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem. 2014;289:34472\u201381. https:\/\/doi.org\/10.1074\/jbc.R114.601351.","journal-title":"J Biol Chem"},{"key":"872_CR122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","volume":"12","author":"NB Hastings","year":"2017","unstructured":"Hastings NB, Wang X, Song L, et al. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener. 2017;12:39. https:\/\/doi.org\/10.1186\/s13024-017-0181-0.","journal-title":"Mol Neurodegener"},{"key":"872_CR123","doi-asserted-by":"publisher","unstructured":"Rostgaard N, Jul PH, Garmer M, Volbracht C. Increasing O-GlcNAcylation attenuates tau hyperphosphorylation and behavioral impairment in rTg4510 tauopathy mice. JIN 2023;22. https:\/\/doi.org\/10.31083\/j.jin2205135.","DOI":"10.31083\/j.jin2205135"},{"key":"872_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-9-42","volume":"9","author":"SA Yuzwa","year":"2014","unstructured":"Yuzwa SA, Shan X, Jones BA, et al. Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau\/APP mutant mice. Mol Neurodegener. 2014;9: 42. https:\/\/doi.org\/10.1186\/1750-1326-9-42.","journal-title":"Mol Neurodegener"},{"key":"872_CR125","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","volume":"79","author":"DL Graham","year":"2014","unstructured":"Graham DL, Gray AJ, Joyce JA, et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology. 2014;79:307\u201313. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.11.025.","journal-title":"Neuropharmacology"},{"key":"872_CR126","unstructured":"Fleisher A, editor. PROSPECT-ALZ: results of the phase 2 study of ceperognastat, an orally available o-linked n-acetyl glucosaminidase inhibitor for the treatment of early symptomatic Alzheimer\u2019s disease. CTAD; 2024."},{"key":"872_CR127","doi-asserted-by":"publisher","first-page":"873513","DOI":"10.3389\/fendo.2022.873513","volume":"13","author":"MJ Gonzalez-Rellan","year":"2022","unstructured":"Gonzalez-Rellan MJ, Fondevila MF, Dieguez C, Nogueiras R. O-GlcNAcylation: a sweet hub in the regulation of glucose metabolism in health and disease. Front Endocrinol (Lausanne). 2022;13:873513. https:\/\/doi.org\/10.3389\/fendo.2022.873513.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"872_CR128","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrm.2017.22","volume":"18","author":"X Yang","year":"2017","unstructured":"Yang X, Qian K. Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol. 2017;18:452\u201365. https:\/\/doi.org\/10.1038\/nrm.2017.22.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"872_CR129","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","volume":"4","author":"G Salvad\u00f3","year":"2024","unstructured":"Salvad\u00f3 G, Horie K, Barth\u00e9lemy NR, et al. Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model. Nat Aging. 2024;4:694\u2013708. https:\/\/doi.org\/10.1038\/s43587-024-00599-y.","journal-title":"Nat Aging"},{"key":"872_CR130","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/alz.13908","volume":"20","author":"A Leuzy","year":"2024","unstructured":"Leuzy A, Raket LL, Villemagne VL, et al. Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: the CenTauR scale and the joint propagation model. Alzheimers Dement. 2024;20:5833\u201348. https:\/\/doi.org\/10.1002\/alz.13908.","journal-title":"Alzheimers Dement"},{"key":"872_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21: e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"key":"872_CR132","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ana.26620","volume":"93","author":"K Horie","year":"2023","unstructured":"Horie K, Li Y, Barth\u00e9lemy NR, et al. Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in dominantly inherited Alzheimer\u2019s disease. Ann Neurol. 2023;93:1158\u201372. https:\/\/doi.org\/10.1002\/ana.26620.","journal-title":"Ann Neurol"},{"key":"872_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03617-7","author":"K Horie","year":"2025","unstructured":"Horie K, Salvad\u00f3 G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03617-7.","journal-title":"Nat Med"},{"key":"872_CR134","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","volume":"146","author":"H Florian","year":"2023","unstructured":"Florian H, Wang D, Arnold SE, et al. Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain. 2023;146:2275\u201384. https:\/\/doi.org\/10.1093\/brain\/awad024.","journal-title":"Brain"},{"key":"872_CR135","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","volume":"90","author":"K U\u00e9da","year":"1993","unstructured":"U\u00e9da K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:11282\u20136. https:\/\/doi.org\/10.1073\/pnas.90.23.11282.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR136","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","volume":"14","author":"KH Shim","year":"2022","unstructured":"Shim KH, Kang MJ, Youn YC, An SSA, Kim S. Alpha-synuclein: a pathological factor with A\u03b2 and tau and biomarker in Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2022;14:201. https:\/\/doi.org\/10.1186\/s13195-022-01150-0.","journal-title":"Alzheimer's Research & Therapy"},{"key":"872_CR137","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain. 2021;144:2186\u201398. https:\/\/doi.org\/10.1093\/brain\/awab099.","journal-title":"Brain"},{"key":"872_CR138","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/neup.12205","volume":"35","author":"NJ Cairns","year":"2015","unstructured":"Cairns NJ, Perrin RJ, Franklin EE, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology. 2015;35:390\u2013400. https:\/\/doi.org\/10.1111\/neup.12205.","journal-title":"Neuropathology"},{"key":"872_CR139","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"key":"872_CR140","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/1531-8249(199903)45:3<353::aid-ana11>3.0.co;2-4","volume":"45","author":"CF Lippa","year":"1999","unstructured":"Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down\u2019s syndrome brains with Alzheimer\u2019s disease. Ann Neurol. 1999;45:353\u20137. https:\/\/doi.org\/10.1002\/1531-8249(199903)45:3%3c353::aid-ana11%3e3.0.co;2-4.","journal-title":"Ann Neurol"},{"key":"872_CR141","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0022-510x(99)00327-5","volume":"174","author":"W Marui","year":"2000","unstructured":"Marui W, Iseki E, U\u00e9da K, Kosaka K. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer\u2019s disease. J Neurol Sci. 2000;174:81\u20134. https:\/\/doi.org\/10.1016\/s0022-510x(99)00327-5.","journal-title":"J Neurol Sci"},{"key":"872_CR142","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29:1964\u201370. https:\/\/doi.org\/10.1038\/s41591-023-02449-7.","journal-title":"Nat Med"},{"key":"872_CR143","unstructured":"Fraser K, JC, Brown R, Edwards A, Ferber K, Rubel C, Shulman M, Graham D, editors. Distribution of alpha-synuclein co-pathology in mild cognitive impairment (MCI), mild Alzheimer\u2019s disease, and progressive supranuclear palsy clinical trial cohorts. Lisbon: AD\/PD; 2024."},{"key":"872_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/srep40263","volume":"7","author":"NK Majbour","year":"2017","unstructured":"Majbour NK, Chiasserini D, Vaikath NN, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer\u2019s disease. Sci Rep. 2017;7: 40263. https:\/\/doi.org\/10.1038\/srep40263.","journal-title":"Sci Rep"},{"key":"872_CR145","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40478-018-0624-z","volume":"6","author":"D Twohig","year":"2018","unstructured":"Twohig D, Rodriguez-Vieitez E, Sando SB, et al. The relevance of cerebrospinal fluid \u03b1-synuclein levels to sporadic and familial Alzheimer\u2019s disease. Acta Neuropathol Commun. 2018;6:130. https:\/\/doi.org\/10.1186\/s40478-018-0624-z.","journal-title":"Acta Neuropathol Commun"},{"key":"872_CR146","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/alz.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Toja A, Paolini Paoletti F, et al. Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024;20:2444\u201352. https:\/\/doi.org\/10.1002\/alz.13658.","journal-title":"Alzheimers Dement"},{"key":"872_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00381","volume":"13","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li X, Li JD. The roles of post-translational modifications on \u03b1-synuclein in the pathogenesis of Parkinson\u2019s diseases. Front Neurosci. 2019;13: 381. https:\/\/doi.org\/10.3389\/fnins.2019.00381.","journal-title":"Front Neurosci"},{"key":"872_CR148","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/0929866043407174","volume":"11","author":"DM Walsh","year":"2004","unstructured":"Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213\u201328. https:\/\/doi.org\/10.2174\/0929866043407174.","journal-title":"Protein Pept Lett"},{"key":"872_CR149","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med. 2022;387:421\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2202867.","journal-title":"N Engl J Med"},{"key":"872_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03270-6","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, et al. Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03270-6.","journal-title":"Nat Med"},{"key":"872_CR151","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med. 2024;30:1096\u2013103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y.","journal-title":"Nat Med"},{"key":"872_CR152","unstructured":"Singer SZW, Kj\u00e6rsgaard L, Wiedemann J, Kallunki P, Kompus K, J\u00f8rgensen M, Flensburg M, Bidani A, Molinuevo JL, Takeda A, Gr\u00f8nning B, Luthman J. editor Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial [abstract]. Mov Disord. 2024;39(Suppl 1):Abstract 20."},{"key":"872_CR153","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson\u2019s disease. N Engl J Med. 2022;387:408\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203395.","journal-title":"N Engl J Med"},{"key":"872_CR154","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75:1206\u201314. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1487.","journal-title":"JAMA Neurol"},{"key":"872_CR155","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1994690","volume":"13","author":"L Fjord-Larsen","year":"2021","unstructured":"Fjord-Larsen L, Thougaard A, Wegener KM, et al. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13: 1994690. https:\/\/doi.org\/10.1080\/19420862.2021.1994690.","journal-title":"MAbs"},{"key":"872_CR156","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","volume":"124","author":"A Weihofen","year":"2019","unstructured":"Weihofen A, Liu Y, Arndt JW, et al. Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol Dis. 2019;124:276\u201388. https:\/\/doi.org\/10.1016\/j.nbd.2018.10.016.","journal-title":"Neurobiol Dis"},{"key":"872_CR157","unstructured":"Kallunki P, Will\u00e9n K, Sotty F, et al. The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation. In: Movement disorders. Hoboken: Wiley; 2022."},{"key":"872_CR158","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/mds.29897","volume":"39","author":"J Burr\u00e9","year":"2024","unstructured":"Burr\u00e9 J, Edwards RH, Halliday G, et al. Research priorities on the role of \u03b1-synuclein in Parkinson\u2019s disease pathogenesis. Mov Disord. 2024;39:1663\u201378. https:\/\/doi.org\/10.1002\/mds.29897.","journal-title":"Mov Disord"},{"key":"872_CR159","doi-asserted-by":"publisher","first-page":"19573","DOI":"10.1073\/pnas.1005005107","volume":"107","author":"B Greten-Harrison","year":"2010","unstructured":"Greten-Harrison B, Polydoro M, Morimoto-Tomita M, et al. \u03b1\u03b2\u03b3-synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A. 2010;107:19573\u20138. https:\/\/doi.org\/10.1073\/pnas.1005005107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR160","doi-asserted-by":"publisher","unstructured":"Cole TA, Zhao H, Collier TJ, et al. \u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. JCI Insight 2021;6. https:\/\/doi.org\/10.1172\/jci.insight.135633.","DOI":"10.1172\/jci.insight.135633"},{"key":"872_CR161","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9: eaag0481. https:\/\/doi.org\/10.1126\/scitranslmed.aag0481.","journal-title":"Sci Transl Med"},{"key":"872_CR162","unstructured":"Alnylam. Alnylam R&D day. 2023. https:\/\/capella.alnylam.com\/wp-content\/uploads\/2023\/12\/Alnylam-RD-Day-2023-1.pdf. Accessed 19 Nov 2024."},{"key":"872_CR163","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.chembiol.2020.09.001","volume":"28","author":"L Boike","year":"2021","unstructured":"Boike L, Cioffi AG, Majewski FC, et al. Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. Cell Chem Biol. 2021;28:4-13.e17. https:\/\/doi.org\/10.1016\/j.chembiol.2020.09.001.","journal-title":"Cell Chem Biol"},{"key":"872_CR164","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","volume":"134","author":"N Bengoa-Vergniory","year":"2017","unstructured":"Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017;134:819\u201338. https:\/\/doi.org\/10.1007\/s00401-017-1755-1.","journal-title":"Acta Neuropathol"},{"key":"872_CR165","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer A, Hemicker G, Krismer F, et al. \u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis. Mov Disord Clin Pract. 2023;10:737\u201347. https:\/\/doi.org\/10.1002\/mdc3.13710.","journal-title":"Mov Disord Clin Pract"},{"key":"872_CR166","unstructured":"Meilleur K, Seppi K, Krismer F, et al. SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update [abstract]. Mov Disord. 2024;39(Suppl 1):Abstract 644."},{"key":"872_CR167","first-page":"41","volume":"25\u201326","author":"JR Burke","year":"1991","unstructured":"Burke JR, Roses AD. Genetics of Alzheimer\u2019s disease. Int J Neurol. 1991;25\u201326:41\u201351.","journal-title":"Int J Neurol"},{"key":"872_CR168","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977\u201381. https:\/\/doi.org\/10.1073\/pnas.90.5.1977.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR169","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133. https:\/\/doi.org\/10.1126\/science.8346443.","journal-title":"Science"},{"key":"872_CR170","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523\u20137. https:\/\/doi.org\/10.1038\/nature24016.","journal-title":"Nature"},{"key":"872_CR171","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"YT Lin","year":"2018","unstructured":"Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141-1154.e1147. https:\/\/doi.org\/10.1016\/j.neuron.2018.05.008.","journal-title":"Neuron"},{"key":"872_CR172","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1084\/jem.20190980","volume":"216","author":"Y Shi","year":"2019","unstructured":"Shi Y, Manis M, Long J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216:2546\u201361. https:\/\/doi.org\/10.1084\/jem.20190980.","journal-title":"J Exp Med"},{"key":"872_CR173","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.cell.2022.05.017","volume":"185","author":"J Tcw","year":"2022","unstructured":"Tcw J, Qian L, Pipalia NH, et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell. 2022;185:2213-2233.e2225. https:\/\/doi.org\/10.1016\/j.cell.2022.05.017.","journal-title":"Cell"},{"key":"872_CR174","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-022-05439-w","volume":"611","author":"JW Blanchard","year":"2022","unstructured":"Blanchard JW, Akay LA, Davila-Velderrain J, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769\u201379. https:\/\/doi.org\/10.1038\/s41586-022-05439-w.","journal-title":"Nature"},{"key":"872_CR175","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41593-023-01480-8","volume":"26","author":"MR Nelson","year":"2023","unstructured":"Nelson MR, Liu P, Agrawal A, et al. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26:2104\u201321. https:\/\/doi.org\/10.1038\/s41593-023-01480-8.","journal-title":"Nat Neurosci"},{"key":"872_CR176","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2023.11.029","volume":"187","author":"Y Chen","year":"2024","unstructured":"Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses A\u03b2-induced tau seeding and spread. Cell. 2024;187:428-445.e420. https:\/\/doi.org\/10.1016\/j.cell.2023.11.029.","journal-title":"Cell"},{"key":"872_CR177","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.neuron.2024.01.008","volume":"112","author":"A Chemparathy","year":"2024","unstructured":"Chemparathy A, Le Guen Y, Chen S, et al. APOE loss-of-function variants: compatible with longevity and associated with resistance to Alzheimer\u2019s disease pathology. Neuron. 2024;112:1110-1116.e1115. https:\/\/doi.org\/10.1016\/j.neuron.2024.01.008.","journal-title":"Neuron"},{"key":"872_CR178","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","volume":"628","author":"MS Haney","year":"2024","unstructured":"Haney MS, P\u00e1lovics R, Munson CN, et al. APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia. Nature. 2024;628:154\u201361. https:\/\/doi.org\/10.1038\/s41586-024-07185-7.","journal-title":"Nature"},{"key":"872_CR179","doi-asserted-by":"publisher","first-page":"630502","DOI":"10.3389\/fnins.2021.630502","volume":"15","author":"MA Husain","year":"2021","unstructured":"Husain MA, Laurent B, Plourde M. APOE and Alzheimer\u2019s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. 2021;15:630502. https:\/\/doi.org\/10.3389\/fnins.2021.630502.","journal-title":"Front Neurosci"},{"key":"872_CR180","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"A-C Raulin","year":"2022","unstructured":"Raulin A-C, Doss SV, Trottier ZA, et al. ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17:72. https:\/\/doi.org\/10.1186\/s13024-022-00574-4.","journal-title":"Mol Neurodegener"},{"key":"872_CR181","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667. https:\/\/doi.org\/10.1038\/s41467-019-14279-8.","journal-title":"Nat Commun"},{"key":"872_CR182","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024;30:1284\u201391. https:\/\/doi.org\/10.1038\/s41591-024-02931-w.","journal-title":"Nat Med"},{"key":"872_CR183","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.26864","volume":"95","author":"JM Vance","year":"2024","unstructured":"Vance JM, Farrer LA, Huang Y, et al. Report of the APOE4 National Institute on Aging\/Alzheimer disease sequencing project consortium working group: reducing APOE4 in carriers is a therapeutic goal for Alzheimer\u2019s disease. Ann Neurol. 2024;95:625\u201334. https:\/\/doi.org\/10.1002\/ana.26864.","journal-title":"Ann Neurol"},{"key":"872_CR184","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-022-02467-8","volume":"144","author":"D Sepulveda-Falla","year":"2022","unstructured":"Sepulveda-Falla D, Sanchez JS, Almeida MC, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer\u2019s dementia. Acta Neuropathol. 2022;144:589\u2013601. https:\/\/doi.org\/10.1007\/s00401-022-02467-8.","journal-title":"Acta Neuropathol"},{"key":"872_CR185","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1056\/NEJMoa2308583","volume":"390","author":"YT Quiroz","year":"2024","unstructured":"Quiroz YT, Aguillon D, Aguirre-Acevedo DC, et al. APOE3 christchurch heterozygosity and autosomal dominant Alzheimer\u2019s disease. N Engl J Med. 2024;390:2156\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2308583.","journal-title":"N Engl J Med"},{"key":"872_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.710683","volume":"13","author":"AD Snow","year":"2021","unstructured":"Snow AD, Cummings JA, Lake T. The unifying hypothesis of Alzheimer\u2019s disease: heparan sulfate proteoglycans\/glycosaminoglycans are key as first hypothesized over 30 years ago. Front Aging Neurosci. 2021;13: 710683. https:\/\/doi.org\/10.3389\/fnagi.2021.710683.","journal-title":"Front Aging Neurosci"},{"key":"872_CR187","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-016-0099-y","volume":"11","author":"Y Fu","year":"2016","unstructured":"Fu Y, Zhao J, Atagi Y, et al. Apolipoprotein E lipoprotein particles inhibit amyloid-\u03b2 uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener. 2016;11:37. https:\/\/doi.org\/10.1186\/s13024-016-0099-y.","journal-title":"Mol Neurodegener"},{"key":"872_CR188","doi-asserted-by":"publisher","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","volume":"110","author":"BB Holmes","year":"2013","unstructured":"Holmes BB, DeVos SL, Kfoury N, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138-3147. https:\/\/doi.org\/10.1073\/pnas.1301440110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR189","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN, Luna G, Guzman E, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2156-5.","journal-title":"Nature"},{"key":"872_CR190","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.1021\/bi8003999","volume":"47","author":"Y Yamauchi","year":"2008","unstructured":"Yamauchi Y, Deguchi N, Takagi C, et al. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry. 2008;47:6702\u201310. https:\/\/doi.org\/10.1021\/bi8003999.","journal-title":"Biochemistry"},{"key":"872_CR191","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-020-00413-4","volume":"15","author":"Z Li","year":"2020","unstructured":"Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:63. https:\/\/doi.org\/10.1186\/s13024-020-00413-4.","journal-title":"Mol Neurodegener"},{"key":"872_CR192","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1126\/scitranslmed.aaz4564","volume":"13","author":"G Sienski","year":"2021","unstructured":"Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med. 2021;13:13. https:\/\/doi.org\/10.1126\/scitranslmed.aaz4564.","journal-title":"Sci Transl Med"},{"key":"872_CR193","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","volume":"24","author":"Z Yin","year":"2023","unstructured":"Yin Z, Rosenzweig N, Kleemann KL, et al. APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGF\u03b2-mediated checkpoints. Nat Immunol. 2023;24:1839\u201353. https:\/\/doi.org\/10.1038\/s41590-023-01627-6.","journal-title":"Nat Immunol"},{"key":"872_CR194","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41590-023-01640-9","volume":"24","author":"CC Liu","year":"2023","unstructured":"Liu CC, Wang N, Chen Y, et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer\u2019s disease. Nat Immunol. 2023;24:1854\u201366. https:\/\/doi.org\/10.1038\/s41590-023-01640-9.","journal-title":"Nat Immunol"},{"key":"872_CR195","unstructured":"Kim Johnson MK, Stephen Kaminsky, Gianni Amato, Nithya Selvan, Richie Khanna, Sandi See Tai, Ronald Crystal, editor LB4 - Safety and Preliminary Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer\u2019s Disease \u2013 Interim Data from a Phase 1\/2, Open-Label, 52-Week, Multicenter Study. J Prev Alzheimer's Dis. 2025;12(Suppl 1):Abstract LB04."},{"key":"872_CR196","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","volume":"80","author":"ME Belloy","year":"2023","unstructured":"Belloy ME, Andrews SJ, Le Guen Y, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 2023;80:1284\u201394. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3599.","journal-title":"JAMA Neurol"},{"key":"872_CR197","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/alz.13703","volume":"20","author":"CM Ferguson","year":"2024","unstructured":"Ferguson CM, Hildebrand S, Godinho B, et al. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:2632\u201352. https:\/\/doi.org\/10.1002\/alz.13703.","journal-title":"Alzheimers Dement"},{"key":"872_CR198","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/ana.26043","volume":"89","author":"A Litvinchuk","year":"2021","unstructured":"Litvinchuk A, Huynh TV, Shi Y, et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model. Ann Neurol. 2021;89:952\u201366. https:\/\/doi.org\/10.1002\/ana.26043.","journal-title":"Ann Neurol"},{"key":"872_CR199","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1093\/nar\/gkae100","volume":"52","author":"CM Ferguson","year":"2024","unstructured":"Ferguson CM, Godinho B, Echeverria D, et al. A combinatorial approach for achieving CNS-selective RNAi. Nucleic Acids Res. 2024;52:5273\u201384. https:\/\/doi.org\/10.1093\/nar\/gkae100.","journal-title":"Nucleic Acids Res"},{"key":"872_CR200","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"TV Huynh","year":"2017","unstructured":"Huynh TV, Liao F, Francis CM, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron. 2017;96:1013-1023.e1014. https:\/\/doi.org\/10.1016\/j.neuron.2017.11.014.","journal-title":"Neuron"},{"key":"872_CR201","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/alz.12165","volume":"16","author":"KL Rasmussen","year":"2020","unstructured":"Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. APOE and dementia - resequencing and genotyping in 105,597 individuals. Alzheimers Dement. 2020;16:1624\u201337. https:\/\/doi.org\/10.1002\/alz.12165.","journal-title":"Alzheimers Dement"},{"key":"872_CR202","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1002\/alz.14224","volume":"20","author":"YI Deza-Lougovski","year":"2024","unstructured":"Deza-Lougovski YI, Weiss LM, Horton HM, et al. Circulating apoE4 protein levels from dried blood spots predict cognitive function in a large population-based survey setting. Alzheimers Dement. 2024;20:7613\u201323. https:\/\/doi.org\/10.1002\/alz.14224.","journal-title":"Alzheimers Dement"},{"key":"872_CR203","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaneurol.2014.2011","volume":"71","author":"AC Mak","year":"2014","unstructured":"Mak AC, Pullinger CR, Tang LF, et al. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71:1228\u201336. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2011.","journal-title":"JAMA Neurol"},{"key":"872_CR204","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.immuni.2024.09.014","volume":"57","author":"S Kaji","year":"2024","unstructured":"Kaji S, Berghoff SA, Spieth L, et al. Apolipoprotein E aggregation in microglia initiates Alzheimer\u2019s disease pathology by seeding \u03b2-amyloidosis. Immunity. 2024;57:2651-2668.e2612. https:\/\/doi.org\/10.1016\/j.immuni.2024.09.014.","journal-title":"Immunity"},{"key":"872_CR205","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/ana.26351","volume":"91","author":"M Gratuze","year":"2022","unstructured":"Gratuze M, Jiang H, Wang C, et al. APOE antibody inhibits A\u03b2-associated tau seeding and spreading in a mouse model. Ann Neurol. 2022;91:847\u201352. https:\/\/doi.org\/10.1002\/ana.26351.","journal-title":"Ann Neurol"},{"key":"872_CR206","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1126\/scitranslmed.abd7522","volume":"13","author":"M Xiong","year":"2021","unstructured":"Xiong M, Jiang H, Serrano JR, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13:13. https:\/\/doi.org\/10.1126\/scitranslmed.abd7522.","journal-title":"Sci Transl Med"},{"key":"872_CR207","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40478-015-0250-y","volume":"3","author":"F Liao","year":"2015","unstructured":"Liao F, Zhang TJ, Jiang H, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol Commun. 2015;3:70. https:\/\/doi.org\/10.1186\/s40478-015-0250-y.","journal-title":"Acta Neuropathol Commun"},{"key":"872_CR208","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41583-023-00776-9","volume":"25","author":"J Blumenfeld","year":"2024","unstructured":"Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024;25:91\u2013110. https:\/\/doi.org\/10.1038\/s41583-023-00776-9.","journal-title":"Nat Rev Neurosci"},{"key":"872_CR209","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1073\/pnas.151254698","volume":"98","author":"Y Huang","year":"2001","unstructured":"Huang Y, Liu XQ, Wyss-Coray T, et al. Apolipoprotein E fragments present in Alzheimer\u2019s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98:8838\u201343. https:\/\/doi.org\/10.1073\/pnas.151254698.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR210","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1434398100","volume":"100","author":"FM Harris","year":"2003","unstructured":"Harris FM, Brecht WJ, Xu Q, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer\u2019s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:10966\u201371. https:\/\/doi.org\/10.1073\/pnas.1434398100.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"872_CR211","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","volume":"26","author":"J Zhao","year":"2017","unstructured":"Zhao J, Davis MD, Martens YA, et al. APOE \u03b54\/\u03b54 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet. 2017;26:2690\u2013700. https:\/\/doi.org\/10.1093\/hmg\/ddx155.","journal-title":"Hum Mol Genet"},{"key":"872_CR212","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamaneurol.2013.396","volume":"70","author":"AJ Hanson","year":"2013","unstructured":"Hanson AJ, Bayer-Carter JL, Green PS, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013;70:972\u201380. https:\/\/doi.org\/10.1001\/jamaneurol.2013.396.","journal-title":"JAMA Neurol"},{"key":"872_CR213","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1471-4159.2004.02183.x","volume":"88","author":"Y Liang","year":"2004","unstructured":"Liang Y, Lin S, Beyer TP, et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem. 2004;88:623\u201334. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02183.x.","journal-title":"J Neurochem"},{"key":"872_CR214","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14728222.2011.594043","volume":"15","author":"S Mandrekar-Colucci","year":"2011","unstructured":"Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer\u2019s disease. Expert Opin Ther Targets. 2011;15:1085\u201397. https:\/\/doi.org\/10.1517\/14728222.2011.594043.","journal-title":"Expert Opin Ther Targets"},{"key":"872_CR215","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neuron.2023.10.023","volume":"112","author":"A Litvinchuk","year":"2024","unstructured":"Litvinchuk A, Suh JH, Guo JL, et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. 2024;112:384-403.e388. https:\/\/doi.org\/10.1016\/j.neuron.2023.10.023.","journal-title":"Neuron"},{"key":"872_CR216","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tips.2012.03.013","volume":"33","author":"T Jakobsson","year":"2012","unstructured":"Jakobsson T, Treuter E, Gustafsson J, Steffensen KR. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci. 2012;33:394\u2013404. https:\/\/doi.org\/10.1016\/j.tips.2012.03.013.","journal-title":"Trends Pharmacol Sci"},{"key":"872_CR217","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrd4280","volume":"13","author":"C Hong","year":"2014","unstructured":"Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13:433\u201344. https:\/\/doi.org\/10.1038\/nrd4280.","journal-title":"Nat Rev Drug Discov"},{"key":"872_CR218","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","volume":"609","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Fan Q, Luo X, et al. Brain-restricted mTOR inhibition with binary pharmacology. Nature. 2022;609:822\u20138. https:\/\/doi.org\/10.1038\/s41586-022-05213-y.","journal-title":"Nature"},{"key":"872_CR219","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.chembiol.2020.09.002","volume":"28","author":"U Seneviratne","year":"2021","unstructured":"Seneviratne U, Huang Z, Am Ende CW, et al. Photoaffinity labeling and quantitative chemical proteomics identify LXR\u03b2 as the functional target of enhancers of astrocytic apoE. Cell Chem Biol. 2021;28:148-157.e147. https:\/\/doi.org\/10.1016\/j.chembiol.2020.09.002.","journal-title":"Cell Chem Biol"},{"key":"872_CR220","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/alz.13436","volume":"20","author":"C Marino","year":"2024","unstructured":"Marino C, Perez-Corredor P, O\u2019Hare M, et al. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement. 2024;20:819\u201336. https:\/\/doi.org\/10.1002\/alz.13436.","journal-title":"Alzheimers Dement"},{"key":"872_CR221","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/alz.12287","volume":"17","author":"AJ Griswold","year":"2021","unstructured":"Griswold AJ, Celis K, Bussies PL, et al. Increased APOE \u03b54 expression is associated with the difference in Alzheimer\u2019s disease risk from diverse ancestral backgrounds. Alzheimers Dement. 2021;17:1179\u201388. https:\/\/doi.org\/10.1002\/alz.12287.","journal-title":"Alzheimers Dement"},{"key":"872_CR222","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318. https:\/\/doi.org\/10.1038\/nrneurol.2012.263.","journal-title":"Nat Rev Neurol"},{"key":"872_CR223","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501\u201318. https:\/\/doi.org\/10.1038\/s41582-019-0228-7.","journal-title":"Nat Rev Neurol"},{"key":"872_CR224","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(20)30367-6.","journal-title":"Lancet"},{"key":"872_CR225","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G, et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement (N Y). 2025;11:e70098. https:\/\/doi.org\/10.1002\/trc2.70098.","journal-title":"Alzheimers Dement (N Y)"},{"key":"872_CR226","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13024-021-00467-y","volume":"16","author":"E McDade","year":"2021","unstructured":"McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer Disease: A call to arms. Mol Neurodegener. 2021;16:49. https:\/\/doi.org\/10.1186\/s13024-021-00467-y.","journal-title":"Mol Neurodegener"},{"key":"872_CR227","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00401-013-1177-7","volume":"126","author":"PL McGeer","year":"2013","unstructured":"McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126:479\u201397. https:\/\/doi.org\/10.1007\/s00401-013-1177-7.","journal-title":"Acta Neuropathol"},{"key":"872_CR228","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","volume":"12","author":"AG Efthymiou","year":"2017","unstructured":"Efthymiou AG, Goate AM. Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43. https:\/\/doi.org\/10.1186\/s13024-017-0184-x.","journal-title":"Mol Neurodegener"},{"key":"872_CR229","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1211851.","journal-title":"N Engl J Med"},{"key":"872_CR230","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368:107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1211103.","journal-title":"N Engl J Med"},{"key":"872_CR231","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1440-1789.2010.01174.x","volume":"31","author":"JI Satoh","year":"2011","unstructured":"Satoh JI, Tabunoki H, Ishida T, et al. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology. 2011;31:363\u201375. https:\/\/doi.org\/10.1111\/j.1440-1789.2010.01174.x.","journal-title":"Neuropathology"},{"key":"872_CR232","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.201709069","volume":"217","author":"DV Hansen","year":"2017","unstructured":"Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer\u2019s disease. J Cell Biol. 2017;217:459\u201372. https:\/\/doi.org\/10.1083\/jcb.201709069.","journal-title":"J Cell Biol"},{"key":"872_CR233","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli RC, Sierra A, Stevens B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron. 2022;110:3458\u201383. https:\/\/doi.org\/10.1016\/j.neuron.2022.10.020.","journal-title":"Neuron"},{"key":"872_CR234","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","volume":"360","author":"GM Savva","year":"2009","unstructured":"Savva GM, Wharton SB, Ince PG, et al. Age, Neuropathology, and Dementia. N Engl J Med. 2009;360:2302\u20139. https:\/\/doi.org\/10.1056\/NEJMoa0806142.","journal-title":"N Engl J Med"},{"key":"872_CR235","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen PS, DuBois B, et al. Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther. 2016;8:39. https:\/\/doi.org\/10.1186\/s13195-016-0207-9.","journal-title":"Alzheimers Res Ther"},{"key":"872_CR236","doi-asserted-by":"publisher","first-page":"e12073","DOI":"10.1002\/trc2.12073","volume":"6","author":"SP Salloway","year":"2020","unstructured":"Salloway SP, Sevingy J, Budur K, et al. Advancing combination therapy for Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2020;6:e12073. https:\/\/doi.org\/10.1002\/trc2.12073.","journal-title":"Alzheimers Dement (N Y)"},{"key":"872_CR237","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","volume":"38","author":"JL Cummings","year":"2024","unstructured":"Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J. Alzheimer\u2019s disease: combination therapies and clinical trials for combination therapy development. CNS Drugs. 2024;38:613\u201324. https:\/\/doi.org\/10.1007\/s40263-024-01103-1.","journal-title":"CNS Drugs"},{"key":"872_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100001","volume":"12","author":"J Cummings","year":"2025","unstructured":"Cummings J, Gold M, Mintun M, et al. Key considerations for combination therapy in Alzheimer\u2019s clinical trials: Perspectives from an expert advisory board convened by the Alzheimer\u2019s drug discovery foundation. J Prev Alzheimers Dis. 2025;12: 100001. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100001.","journal-title":"J Prev Alzheimers Dis"},{"key":"872_CR239","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/dddt.S86463","volume":"10","author":"WJ Deardorff","year":"2016","unstructured":"Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease. Drug Des Devel Ther. 2016;10:3267\u201379. https:\/\/doi.org\/10.2147\/dddt.S86463.","journal-title":"Drug Des Devel Ther"},{"key":"872_CR240","volume-title":"Clinical trial design for concurrent anti-amyloid, anti-tau antibody therapy for sporadic AD","year":"2025","unstructured":"Doherty T, editor. Clinical trial design for concurrent anti-amyloid, anti-tau antibody therapy for sporadic AD. Vienna: AD\/PD; 2025."}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00872-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:52:44Z","timestamp":1757364764000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00872-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":240,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00872-7","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HH, AW, JG are employees of Biogen and may own stock. TB, CL, KG\u00a0and DMW are former employees of Biogen and may own stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}